Skip to Content

CanBas Co Ltd 4575 Stock Quote

| Rating as of

Morningstar‘s Stock Analysis 4575

Valuation
Currency in JPY
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics 4575

Company Profile 4575

Business Description

CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.

Contact
9 Toriyoko-cho
Shizuoka, 410-0891, Japan
T +81 559543666
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Jun 30, 2019
Employees 12